Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and
Ribavirin (RBV) in patients with genotype 2 hepatitis C, who relapsed after previous
treatment.